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Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear
Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via
an IL-1–Mediated Mechanism
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Background-—Hypertension is a complex condition and a common cardiovascular risk factor. Dietary docosahexaenoic acid (DHA)
modulates atherosclerosis and hypertension, possibly via an inflammatory mechanism. IL-1 (interleukin 1) has an established role
in atherosclerosis and inflammation, although whether IL-1 inhibition modulates blood pressure is unclear.
Methods and Results-—Male apoE/ (apolipoprotein E–null) mice were fed either a high fat diet or a high fat diet plus DHA
(300 mg/kg per day) for 12 weeks. Blood pressure and cardiac function were assessed, and effects of DHA on wall shear stress
and atherosclerosis were determined. DHA supplementation improved left ventricular function, reduced wall shear stress and
oscillatory shear at ostia in the descending aorta, and significantly lowered blood pressure compared with controls
(119.57 versus 159.73 mm Hg, P<0.001, n=4 per group). Analysis of atheroma following DHA feeding in mice demonstrated
a 4-fold reduction in lesion burden in distal aortas and in brachiocephalic arteries (P<0.001, n=12 per group). In addition, DHA
treatment selectively decreased plaque endothelial IL-1b (P<0.01).
Conclusions-—Our findings revealed that raised blood pressure can be reduced by inhibiting IL-1 indirectly by administration of
DHA in the diet through a mechanism that involves a reduction in wall shear stress and local expression of the proinflammatory
cytokine IL-1b. ( J Am Heart Assoc. 2018;7:e008757. DOI: 10.1161/JAHA.118.008757.)
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H ypertension is a major healthcare concern, given itsprevalence among the population and its devastating
complications, namely, stroke and ischemic heart disease
(IHD).1 Evidence suggests that hypertension and dyslipidemia
are the underlying risk factors in IHD.2 In the search for a
novel therapeutic intervention, the importance of inflamma-
tory molecules and immune cell involvement in the disease is
increasing.
Arterial inflammation has been shown in patients with
systemic hypertension.3 Cytokines, including IL-1 (interleukin
1), are key mediators in inflammation.4,5 In pathological
vascular disease, the main role of IL-1 is to regulate leukocyte
migration and accumulation.6,7 IL-1 has also been shown to
promote endothelial cell dysfunction,8 a cardinal process in
the pathogenesis of hypertension and atherosclerosis. Several
studies, in animals9,10 and humans,11,12 have postulated a key
role for IL-1b in the pathogenesis of atherosclerosis and
clinical sequelae such as hypertension.13,14
Recent studies suggest that dietary fat, especially satu-
rated fatty acids, are deleterious for atherosclerosis and
hypertension.15 Although saturated fat is proatherogenic, x-3
fatty acids (n3FA), especially docosahexaenoic acid (DHA;
22:6n-3), are known to be anti-atherogenic,16 with multiple
underlying mechanisms.17 Consequently, it has been sug-
gested that patients at high risk of the disease need to
increase their fish and fish-derived food intake and decrease
saturated fat intake.18,19
From the Department of Infection, Immunity and Cardiovascular Disease
(M.A.A., J.C., A.R., P.C.E., S.E.F.) and INSIGNEO Institute for in silico Medicine
& Department of Computer Science (M.-C.V.-U.), University of Sheffield, United
Kingdom; BHF Centre of Excellence, University of Edinburgh, United Kingdom
(P.H., J.W.); Department of Engineering and Mathematics, Sheffield Hallam
University, United Kingdom (T.S.); University of St Andrews, United Kingdom
(D.C.).
An accompanyingData S1 is available at http://jaha.ahajournals.org/content/
7/13/e008757/DC1/embed/inline-supplementary-material-1.pdf
Correspondence to: Sheila E. Francis, PhD, Department of Infection,
Immunity and Cardiovascular Disease, Faculty of Medicine, Dentistry &
Health, University of Sheffield, Medical School, Beech Hill Road, Sheffield S10
2RX, United Kingdom. E-mail: s.francis@sheffield.ac.uk
Received March 8, 2018; accepted May 30, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduc-
tion in any medium, provided the original work is properly cited.
DOI: 10.1161/JAHA.118.008757 Journal of the American Heart Association 1
ORIGINAL RESEARCH
D
ow
nloaded from
 http://ahajournals.org by on June 11, 2020
Epidemiological, case–control, and prospective clinical
studies have demonstrated positive effects of n3FAs in the
reduction of cardiovascular mortality rates among IHD
patients.20 These effects have been ascribed to the improve-
ment of cardiovascular risk profiles, resulting in disease
prevention21; however, the data on IHD and hypertension are
less robust. Clinical trials in post–myocardial infarction
patients have suggested that DHA, specifically, may exert a
therapeutic effect, particularly on hypertension and the risk of
reinfarction,22 although this has not been shown unequivo-
cally or linked with atherosclerotic plaque stabilization/
regression.23,24 DHA supplementation decreased blood pres-
sure in spontaneously hypertensive rats25,26 and in a dog
model of hypertension,27 but no data are available for mouse
models with atherosclerosis.
Consequently, it is clear that DHA has broad anti-
inflammatory effects, but whether it has inhibitory effects
on IL-1–dependent inflammation in the setting of hyperten-
sion and the mechanisms involved needs further elucidation.
We aimed to investigate whether DHA supplementation
in mice could alter vascular contractility via an IL-1b–
mediated mechanism, contributing to blood pressure reduc-
tion in experimental atherosclerosis. We showed that DHA
reduces wall shear stress (WSS; calculated by computa-
tional flow dynamics) in the descending aorta, especially at
ostia, and that this is associated with significantly
decreased arterial blood pressure, enhanced left ventricular
(LV) function, and a reduction in intraplaque inflammation
directed by IL-1b.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure; however,
requests for specific elements of the these materials will be
considered.
Detailed methods can be found in the supplemental
information (Data S1).
Diet-Induced Hypertension in Mice
Male ApoE/ (apolipoprotein E–null) mice were bred in-
house at the University of Sheffield. Food and water were
given ad libitum in a controlled environment (temperature 22–
25°C, humidity 555%, and 12-hour light cycle). Starting at
8 weeks of age, the mice were housed individually and
randomly separated into 1 of 2 groups (n=12 per group). The
control group was fed a Western-type high-fat diet (HFD)
containing 21% (wt/wt) fat, 0.15% (wt/wt) cholesterol, and
0.296% (wt/wt) sodium, whereas the DHA-treated group
received the HFD and DHA (99% purified). In this model, mice
have raised blood pressure as a result of HFD feeding.9
DHA feeding was achieved by mixing the DHA with jelly
using a previously described “jelly-delivery” protocol28 at a
final concentration of 300 mg/kg per day. Briefly, DHA was
placed into separate shallow molds (12 doses of DHA per
mold). Flavored jelly was dissolved in hot water, according to
the manufacturer’s instructions and allowed to cool, then
poured into each mold and mixed with the DHA to achieve an
even suspension. Molds were placed immediately in a freezer
and later cut into 12 equal cubes, measuring 1 cm3,
containing a single dose of drug. The mice were monitored
daily for their DHA intake. Body weights were measured
weekly over 12 weeks. All animal care and procedures were
closely conducted under ASPA 1986, UK and in accordance
with Home Office guidelines under license 70/7992.
Biochemistry
To confirm absorption of DHA, red blood cell x-3 composition
and indexes were measured by gas chromatography in pooled
blood samples of the mice (4 mice per group).29
Blood Pressure Analysis
Systolic and diastolic blood pressure was measured in the mice
using a Visitech tail-cuff system, as described previously.9
Echocardiography
Echocardiograms were performed in the mice fed either a
HFD alone or a HFD and DHA over 12 weeks, as described
previously.30
Clinical Perspective
What Is New?
• In a mouse model of atherosclerosis, supplementation of a
Western diet with docosahexaenoic acid improved left
ventricular function, reduced aberrant hemodynamic flow
patterns in the aorta, and lowered blood pressure.
• Atheroma burden was reduced 4-fold in the docosahex-
aenoic acid–supplemented group at 2 anatomic sites.
• IL-1 (interleukin 1) is plausibly implicated in the mechanism
for these effects because docosahexaenoic acid selectively
decreased plaque endothelial IL-1b.
What Are the Clinical Implications?
• Regular supplementation of the diet with docosahexaenoic
acid alters blood-flow patterns in the vasculature, reducing
local IL-1–induced inflammation and atherosclerosis and,
consequently, lowering blood pressure.
• Given the importance of the CANTOS (Canakinumab
Antiinflammatory Thrombosis Outcome Study), our data
suggest that strategies that control local IL-1b may also be
useful in hypertension.
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Atherosclerosis Analysis
The extent of atherosclerosis was assessed in cross-sectional
aortic sinus and brachiocephalic sections, as described.31
Mean lesion size was calculated from measurements of 5 sinus
sections starting from the 3 cusp area. Analysis was conducted
blinded per individual animal and experimental conditions, and
measurements from all sections averaged per mouse. A second
assessment of atherosclerosis was conducted in the whole
aortas using an en face method.32 Lesion areas were analyzed
using a NIS-Elements software system (Nikon).
Immunohistochemical Analysis
Paraffin-embedded aortic sections were immunostained, as
described previously.33 Heat-mediated antigen retrieval was
performed using citrate buffer (pH 6.0). Following blockage of
nonspecific binding by incubationwith either 1% (wt/vol) bovine
serum albumin or 1% (wt/vol) nonfat milk, the sections were
incubated with the relevant primary antibody overnight at 4°C
(anti–IL-1b, 1:100, or anti–IL-1ra, 1:100). Positive staining was
detected using a biotinylated secondary antibody followed by
an avidin/biotin complex with horse radish peroxidase label
(ABC-HRP complex) and visualized using DAB. Cell nuclei were
counterstained using hematoxylin. Images were taken and
analyzed using NIS-Elements software.
Computational Fluid Dynamics
Computational fluid dynamics of the unsteady flow in the aortic
branch, including the ostia, was performed using the unsteady
Navier-Stokes codeANSYSFluent 17.1, following a similarmodel
to that used by Luong et al.34 The geometry of a single
representative murine aortic geometry was derived from post-
mortem optical projection tomography.35 Briefly, the thoracic
descending aorta was carefully dissected and embedded in 1.5%
(wt/vol) low-melting-point agarose gel. The sample was dehy-
drated in pure ethanol (twice, 24 hours each) and optically
cleared in BABB (benzyl alcohol and benzyl benzoate at a 1:2
ratio) for 24 hours. The aorta was scanned using a Bioptonics
3001 tomograph (Bioptonics). Projection images (9400) were
obtained with a 0.9° rotation step, and these were reconstructed
into a 3-dimensional image that contained a stack of 1024 cross-
sections using NRecon software (Skyscan). The 3-dimensional
image was then triangulated into a high-resolution STL (standard
triangle language) surface, and an intermediate surface mesh
comprising 2.2 million triangles was produced using image
processing and reconstruction (ImageJ v1.49u36) and image
segmentation (3-dimensional slicer v4.5.037) software. Further
meshmanipulation and cleaning were performed using Paraview
v4.3.138 and the specialized vascular modeling software
@neuFuse v7.3 to produce a high-resolution mesh comprising
1.3 million triangles. This resolution was chosen as a compro-
mise to accommodate the wide range of length scales from the
aortic arch down to the ostia diameters required in this study.
The lumen was meshed using ANSYS ICEM computational
fluid dynamics, generating a hybrid tetrahedral mesh with a
prismatic boundary layer representation. Based on a mesh
independence analysis,34 a final volume mesh size of 1 million
cells was used to deliver converged WSS, with simulation times
of 36 hours on 4 cores of an Intel i7 3.4 GHz processor. The
geometry was assumed to be rigid. Blood was modeled as a
Newtonian fluid with a dynamic viscosity ofg=0.004 Pa/s and a
density of q=1235 kg/m3. Calculated with a typical maximum
flow speed of V=1 m/s and a hydraulic diameter at the aortic
root of D=1.58 mm, the maximum Reynolds number is
Re ¼ qVDð Þg1 ¼ 488. The flow was thus modeled as laminar.
The inlet boundary condition was a time-dependent
prescribed velocity profile (Dirichlet condition), calculated as
a third-order Bezier spline approximation39 based on a
digitized US Doppler measurement.
Outlet conditions at all exits were von Neumann outlet
conditions with a split of 69.8%, 16%, 8%, and 6% for
descending aorta, innominate, common carotid, and subcla-
vian, respectively, and 0.14% for each of the 12 ostia. All
outlet conditions were in phase with the inlet velocity profile.
Numerical solutions were obtained using cell-based gradi-
ents with second-order pressure, quadratic upwind momen-
tum, and second-order implicit time discretization. Time step
size was chosen as 1/1000th of the cycle time. Three cycles
were simulated to allow for fully developed periodicity, and
the last cycle was evaluated.
Three-dimensional time-dependent WSS data were
exported to calculate the time-averaged WSS magnitude
(TAWSS), the oscillatory shear index (OSI), and transverse
WSS (transWSS):
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Although OSI quantifies the oscillatory character of near
wall flow, transWSS is a metric for instantaneous WSS vector
components that are perpendicular to the mean WSS vector
in the local endothelium plane, as proposed previously.40
Statistical Analysis
Data are expressed as meanSEM and were analyzed using
Prism software (v6; GraphPad). Paired blood pressure data
were analyzed by paired 2-way ANOVA followed by Sidak
posttest. For 2-group comparisons, data were analyzed by
Student t test for normally distributed data. Statistical
significance was achieved when P<0.05.
Results
DHA supplementation of the HFD was well tolerated by the
mice, with no side effects, and absorption was confirmed by
specific changes in free fatty acid composition (increased by
38 lmol/L in DHA-fed mice) in red blood cell membranes
(Figure 1B). The red blood cell x-3 index in the DHA-fed mice
increased by an average of 25% compared with the control
mice (anecdotal observation under experimental conditions;
Figure 1A).
Plasma levels of LDL-C (low-density lipoprotein cholesterol)
in DHA-treated mice were not significantly different from
those in the controls (Figure 1C), but the HDL (high-density
lipoprotein)/cholesterol ratio significantly increased in the
DHA-supplemented mice compared with controls (Figure 1D).
There was no significant change in body weight between the 2
groups (Figure 1E).
We analyzed blood pressure data collected over the
feeding period. At baseline, there was no difference in
starting values between groups. Subsequently, with feeding,
systolic blood pressure rose in both groups until week 5 and
then declined in the DHA-supplemented group only
(132.39.18 versus 146.63.563 mm Hg, respectively,
P<0.05, n=4). This fall in systolic blood pressure in the
DHA-supplemented group continued for a further 7 weeks
(119.57.33 mm Hg in the DHA group compared with
159.72.482 mm Hg, P<0.001 at week 12; Figure 2A).
Diastolic blood pressure in the DHA-fed mice also significantly
decreased compared with the control group (7514.65
versus 100.57.549, respectively; P<0.01; Figure 2B).
Changes in LV wall thickness and function were recorded
using echocardiography and were analyzed at week 0
(baseline) and week 12. In the DHA-supplemented group,
the percentage of LV ejection fraction increased after
12 weeks, although this was not statistically significant
compared with control mice (Figure 2C). However, the change
in ejection fraction between time 0 and 12 weeks showed the
control group experienced a significant decrease, whereas the
DHA group had an increase in ejection fraction (Figure 2D).
LV mass was significantly decreased in the DHA group after
12 weeks (Figure 2E) compared with controls. Collectively,
these data suggest that DHA supplementation may protect
against LV hypertrophy induced by HFD feeding in apoE/
mice, secondary to high blood pressure.
Atherosclerotic lesion analysis showed no difference in
lesion size in the aortic root (Figure 3A and 3B) but a significant
reduction in lesion size in brachiocephalic artery in DHA-
supplemented HFD mice versus controls (Figure 3C and 3D).
The distribution of plaques in the whole thoracic aorta was
significantly altered with DHA feeding, leading to a 4512%
decrease in the total aortic Oil Red O–stained atherosclerotic
area (P<0.001) compared with controls (Figure 3E and 3F).
This effect was localized in the descending aortic plaques only
(a reduction of 305%, P<0.05; Figure 3F), with no effect of
DHA supplementation observed in the aortic arch.
Optical projection tomography imaging of the descending
aorta and its intercostal vessels and reconstruction of slices
to make a 3-dimensional macrogeometry were used to build a
computational fluid dynamic model of blood flow at intercostal
branches. Using flow parameters from our echocardiography
study and estimated boundary conditions from ourselves34
and others,41 simulations of flow showed a reduction in time-
averaged WSS (23.631.9 versus 18.531.5 Pa, P<0.001)
and, more important, both OSI (0.0040.001 versus
0.0030.0002, P<0.01) and transWSS (0.3550.035 versus
0.2850.03 Pa, P<0.001) in mice supplemented with DHA
(Figure 4).
Analysis of inflammatory cytokines showed mice fed a diet
supplemented with DHA had reduced plasma IL-8, regulated
on activation, normal T cell expressed and secreted; CCL5
(RANTES), and MCP-1 (monocyte chemoattractant protein 1),
but there was no change in TNF-a (tumor necrosis factor a)
or IL-1 versus controls (Figure 5A–5F); however, we were
able to measure the apical cytokine IL-1b directly in
atherosclerotic lesions by immunostaining. Although we
saw no difference in IL-1b levels in the lesion as a whole
(Figure 6A), we did observe a significant reduction in
endothelial IL-1b expression in the DHA-supplemented mice
compared with controls (Figure 6B). IL-1a levels did not differ
between groups (Figure 6C). Levels of IL-1ra, however, were
increased in DHA-fed mice (Figure 6D). Concomitantly,
Western blot analysis of aortas showed levels of TLR-4
(Toll-like receptor 4) were reduced following DHA feeding
(Figure 6F). Analysis of aortic sections for macrophages
showed a significant reduction in DHA-treated animals
compared with controls (Figure 6E). There were no differ-
ences in collagen levels (Figure 7) between groups; however,
there was a reduction in smooth muscle cells, analyzed by
Western blotting for smooth muscle actin, in DHA-fed mice
(Figure 6G).
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Discussion
Contemporary primary and secondary therapies for cardio-
vascular disease prevent the progression of atherosclerosis
and stabilize the plaque, providing significant clinical
benefit42; however, not all patients respond to risk factor–
modifying therapy, especially patients with hypertension.43–45
The Ω-3 fatty acids, particularly DHA (a major type of n3FA in
fish oil) and a-linolenic acid (ALA; the most common land-
based type of n3FAs), have been shown to play an important
role in preventive medicine.46,47 A diet supplemented with
n3FAs leads to increased incorporation of the n3FAs (ALA,
DHA, eicosapentaenoic acid) in plasma lipoproteins48
associated with lower rates of plaque vulnerability.49,50 In
clinical studies, however, DHA has been mostly mixed with
eicosapentaenoic acid or given as fish oil, and thus its
individual effects remain obscured. ALA may have a cardio-
protective role; however, the overall evidence is mixed and
remains inconclusive.51,52 Similarly, several animal models of
atherosclerosis have investigated the anti-atherogenic effects
Figure 1. DHA feeding of apoE/ (apolipoprotein E–null) mice induces changes in RBC x-3 fatty acid
compositions without any significant effect on their body weights. A, The x-3 index (percentage) is
enhanced in DHA-fed mice compared with controls. The apoE/ mice were fed an HFD alone (control) or
an HFD and DHA (300 mg/kg per day) for 12 weeks. Data are from pooled blood of n=4 mice per group.
Blood was sampled at the experimental end point. B, Fatty acid composition in RBCs of DHA-fed mice
compared with controls (lmol/L; pooled blood from 4 mice per group). C, Plasma LDL-C (in mmol/L) and
(D) HDL/CHOL ratio, measured enzymatically (n=10 per group). E, Body weights of the mice (in g) were
recorded weekly. Data are shown as meanSEM, analyzed by Student t test (C and D) or 2-way ANOVA
followed by Tukey test (E), *P<0.05. ALA indicates a-linolenic acid (18:3n-3); DHA, docosahexaenoic acid
(22:6n-3); EPA, eicosapentaenoic acid (20:5n-3); ETA, eicosatetraenoic acid (20:4n-3); HDL/CHOL, high-
density lipoprotein/total cholesterol; HFD, high-fat diet; LDL-C, low-density lipoprotein cholesterol; RBC, red
blood cell.
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of n3FAs,53 but these studies also did not directly define
the differential effects of individual n3FAs on atherosclerosis.
To our knowledge, this study is the first to define a
common anti-atherogenic and anti-hypertensive mechanism
of DHA. It is also the first to perform fluid dynamics analysis
of blood flow around the intercostal branches in a mouse and
to suggest a potential mechanism by which DHA alters flow
patterns in the distal aortas, leading to modulation of
inflammation.
It is published that n3FAs have a blood pressure–lowering
effect in both normotensive54,55 and hypertensive56 individ-
uals. In addition, studies using animal models have shown that
fish oil has a generalized blood pressure–lowering effect.57
Nevertheless, as with atherosclerosis, the individual effects of
n3FAs in hypertension are less studied. DHA is more
commonly investigated for its anti-hypertensive effects,27
and there is an endogenous conversion for DHA to eicos-
apentaenoic acid occurring mainly in the liver.58 Conse-
quently, this study focused on the specific effects of DHA on
atherosclerosis-related hypertension.
Our data show that DHA significantly decreases blood
pressure in our experimental model, reinforcing previous
interventional studies in humans59,60 and consistent with a
report that DHA supplementation significantly reduces 24-
hour ambulatory blood pressure in hypercholesterolemic
patients.61 In animal studies, DHA reduces systolic blood
pressure and vascular wall thickness in spontaneously
hypertensive rats25,62 and aldosterone-induced hypertension
in dogs.27 Our study, however, is the first to elucidate the
hypotensive effects of DHA in experimental atherosclerosis
induced in mice by feeding a Western diet.
In contrast, ALA supplementation did not show any
significant impact on blood pressure in atherosclerotic mice
(Mabruka A Alfaidi, PhD, 2017, unpublished data). ALA as an
antihypertensive agent has been studied in a limited number
of studies,63 and the lack of effect on blood pressure with ALA
is at odds with previous clinical studies that demonstrate the
hypotensive effects of ALA in hypertensive individuals.56 Mice,
however, are deficient in the enzyme that is responsible for
the endogenous metabolism of ALA64 and thus may respond
differently to ALA than humans. As such, ALA investigations
were not pursued in this study.
An independent association exists between LV mass and
atherosclerotic coronary disease in patients with IHD,65 and
Figure 2. DHA significantly reduces HFD induced hypertension in apoE/ (apolipoprotein E–null) mice. A, SBP and (B) DBP were measured in
freely moving apoE/ mice fed either HFD alone (control) or HFD and DHA (DHA treated) for 12 weeks (n=4 per group) using a tail-cuff system
(see Methods for details). All data are expressed as meanSEM, analyzed by 2-way ANOVA and Tukey posttest, *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001. Effects of DHA feeding on (C) left ventricular EF (%EF) and change in (D) EF and (E) LVM (in mg). Echocardiographic
data were measured in anesthetized mice and are presented as meanSEM (n=4 per group), analyzed by unpaired Student t test, *P<0.05. DBP,
diastolic blood pressure; DHA, docosahexaenoic acid (22:6n-3); EF, ejection fraction; HFD, high-fat diet; LVM, left ventricular mass; SBP, systolic
blood pressure.
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we observed that supplementation with DHA significantly
attenuated the increase in LV mass after 12 weeks of HFD
feeding in mice. Our finding of a significant reduction of total
aortic tree lesions by DHA is in agreement with another recent
study.66 However, we go further than this and show that DHA
supplementation of a Western diet in mice significantly and
selectively decreases atherosclerosis in the distal parts of the
aorta and brachiocephalic arteries. Such differential
atherosclerotic responses have been reported before but have
not been explained.67 Our novel computational flow analyses
indicate that flow effects are part of the explanation for this,
and we postulate that the effect of DHA is more pronounced in
areas with a high oscillatory or a high transverse component of
the WSS compared with areas where there is high average
WSS. In some locations along the aorta (especially in the arch),
the plaque formation in the control group correlates with high
OSI, whereas in regions with generally low OSI, there seems to
be a correlation with high transWSS. The exact relationship
between these WSS derivatives and atherosclerosis is not yet
fully understood, although hypertensive remodeling of resis-
tance vessels is postulated to be due to a combination of
genetic factors, maladaptation of walls of vessels in the
microcirculation to adverse mechanical conditions, and the
influence of neurohumoral and local trophic factors.68–70
The local anti-inflammatory effect of DHA has been
previously associated with a thickening in the fibrous cap
Figure 3. Differential effects of DHA feeding on lesion development in different areas of the vascular
beds. Male apoE/ (apolipoprotein E–null) mice aged 8 weeks were fed a Western-type HFD alone
(control) or an HFD and jelly containing DHA (DHA treated; 300 mg/kg per day) daily over 12 weeks.
A, Representative images of aortic roots stained with AB/EVG after 12 weeks of feeding (n=12 per group).
Scale bars=100 lm. B, Mean lesion area of aortic root sections, normalized to CSA (n=12). Data are
meanSEM, analyzed by unpaired Student t test, P=ns. C, Representative images of brachiocephalic
sections stained with AB/EVG (scale bars=100 lm). D, Mean lesion area of brachiocephalic arteries,
normalized to CSA. Data are meanSEM, analyzed by unpaired Student t test, 9 or 10 per group,
***P<0.001. E, Representative en face morphometric images of the total aortic lesion area and (F) whole
aortic, aortic arch, and descending aortic lesion area calculated as a percentage of the total surface area of
the whole aorta, showing significant reduction in the total lesion formation in the distal aorta in the DHA
group compared with control. Data are meanSEM, analyzed by 2-way ANOVA and Tukey post-test, 11 or
12 per group, *P<0.05, ***P<0.001. AB/EVG indicates alcian blue and elastic van Gieson; CSA, cross-
sectional area; DHA, docosahexaenoic acid (22:6n-3); HFD, high-fat diet.
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and more stable plaque formation.45 In our study, however,
smooth muscle cell content was decreased and collagen
content was not altered. DHA is known to suppress smooth
muscle cell proliferation in cell culture,20,71 and our data
suggest that the mechanism of atheroprotection mediated by
DHA may be complex, linked to blood flow patterns and WSS
affecting inflammation locally and at distal atheroprone sites.
We suggest that DHA, through modulation of complex
blood flow potentially via changes in viscosity,72 transduces
and inhibits apical inflammatory signals that orchestrate
inflammation in atherosclerosis. Human studies suggest that
supplementing the diet of young males with DHA in fish oil
significantly reduces IL-1b production in LPS (lipopolysac-
charide)-stimulated monocytes.73 In addition, Vijay-Kumar
et al have reported that monocytes harvested from mice fed
fish oil containing DHA produced less IL-1b compared with
controls.74 We found, however, that DHA supplementation in
mice had no effect on the plasma levels of IL-1. The
Figure 4. Flow simulations for descending aortas with intercostal branches dissected from DHA-treated and non–DHA-treated pro-
atherosclerotic mice. Shown are (A) TAWSS magnitude (TAWSS), (B) OSI, and (C) transWSS for left upper, right upper, left lower, and right lower
3 pairs of the ostia (from left to right) for the control group vs the DHA-treated group. Flow characteristics remain similar between control and
DHA-treated vessels but show elevated wall shear stress levels throughout that correlate with the higher maximum flow speed. OSI shows only a
small decrease in DHA-treated animals, located mainly below and between ostia branches. TransWSS is again higher in the control group. DHA
indicates docosahexaenoic acid (22:6n-3); OSI, oscillatory shear index; TAWSS, time-average wall shear stress; transWSS, transverse wall shear
stress.
DOI: 10.1161/JAHA.118.008757 Journal of the American Heart Association 8
DHA Reduces WSS, Atherosclerosis, and Hypertension Alfaidi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on June 11, 2020
discrepancy between our data and these published results
could occur because measurement of cytokines in plasma is
notoriously difficult or because, in our model, DHA may
decrease local production of cytokines such as IL-1b in cells
inside lesions themselves. Indeed, we observed a decrease in
endothelial IL-1b expression in atherosclerotic lesions of
DHA-fed animals versus controls. The primary cellular origin of
IL-1b in atherosclerosis is unclear, but we have previously
shown in coronary atherosclerotic plaques of patients with
IHD that IL-1b is predominantly expressed in relatively large
amounts in the endothelium and vasa vasorum.75 We did
show robust reductions in IL-8, RANTES, and MCP-1 in
plasma, although previous animal studies have reported no
significant correlation between DHA feeding and these plasma
cytokines.76 Most of these studies, however, were small and
used fish oil, with little attention given to specific DHA effects.
Our findings do agree with data from in vitro studies,
particularly from cultured cells, including monocytes and
endothelial cells.77–80 We thus conclude that the atheropro-
tective effect of DHA is transduced by alterations in flow
leading to an arterial environment in which levels of these
plasma chemoattractants are reduced.
Our previous studies have shown that atherosclerotic mice
treated with anakinra or the murine version of canakinumab,
as well as IL-1R1 knockout mice, have reduced blood pressure
and atherosclerosis formation compared with controls9,81 and
that this finding is replicated in our DHA-fed mice. The
reduction in IL-1-induced biomarkers (IL-8, MCP-1, RANTES) in
mice fed DHA is also replicated in these mice when IL-1
signaling is inhibited. This combined with a reduction in TLR-4
levels and an increase in IL-1ra levels in DHA-fed mice all
suggest DHA is acting via an IL-1 mechanism (Figure 8).
Furthermore, and of potential clinical relevance, unpublished
data from the IL-A HEART study82,83 in our group show that in
a post hoc secondary analysis of blood pressure data, systolic
and diastolic blood pressure and mean arterial pressure
decreased in the group receiving IL-1ra (baseline versus day
14: 131.42.4 versus 124.71.6 mm Hg, systolic, P<0.01;
75.21.5 versus 71.11.2 mm Hg, diastolic, P=ns;
93.91.7 versus 88.61.2 mm Hg, mean arterial pressure,
P<0.05; n=76 patients [IL-1ra] and n=71 [placebo], t test).
Given other recent data,84 we speculate that strategies to
block IL-1 signaling directly could modulate hypertension.
Our DHA study does have limitations. It is not clear, for
example, whether the effect on atherosclerosis is related to a
direct effect of DHA on blood pressure or whether the
opposite applies. The same limitation applies to our previous
studies that lowered blood pressure by inhibiting IL-1
signaling directly, without using DHA. To fully address this
question, analysis of atherosclerosis in a study group whereby
blood pressure is lowered by a non-DHA and non–IL-1
mechanism would need to be performed.
Figure 5. Plasma pro-inflammatory profiles in response to DHA feeding. Male apoE/ (apolipoprotein E–null) mice, from 8 weeks of age,
were fed either an HFD alone or an HFD and DHA (300 mg/kg per day) daily. Following 12 weeks of diet, freshly isolated plasma was analyzed
using cytometric bead arrays for (A) IL-8, (B) MCP-1, (C) RANTES, (D) TNF-a, (E) IL-1b, and (F) IL-1a (in pg/mL; 8–10 per group). Data are
expressed as meanSEM, analyzed by unpaired Student t test, *P<0.05, **P<0.01. DHA indicates docosahexaenoic acid (22:6n-3); HFD, high-
fat diet; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; TNF-a, tumor necrosis factor a.
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Figure 6. IL-1 distribution in aortic atherosclerosis and lesion characteristics in response to DHA feeding.
Male apoE/ (apolipoprotein E–null) mice, from 8 weeks of age, were fed either an HFD alone or an HFD
and DHA (300 mg/kg per day) daily. Following 12 weeks of diet, immunostaining, measured semiquan-
titatively as a percentage of total lesions, showed no difference in (A) IL-1b or (B) IL-1a. The number of
IL-1b–positive ECs, measured semiquantitatively as a percentage of total number of ECs, is lower in DHA-
treated mice compared with control (B). D, IL-1ra is increased and (E) Mac-3 (CD107b) is decreased in DHA-
treated animals. Image analysis was performed using NIS-Elements software, and data are represented as
meanSEM, 6 to 8 per group. Student t tests indicate a significant difference with *P<0.05; **P<0.01.
Western blot analysis of mouse aortas showed (F) TLR-4 and (G) SMA levels are significantly decreased
following DHA feeding. DHA indicates docosahexaenoic acid (22:6n-3); EC, endothelial cell; HFD, high-fat
diet; IL, interleukin; SMA, smooth muscle actin; TLR-4, Toll-like receptor 4.
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In conclusion, our study provides the first evidence that
regular supplementation of DHA in the proatherogenic diet of
mice influences arterial walls in such a way as to alter blood
flow patterns distally in the vascular tree. We suggest that this
may lead to reduced local inflammation (IL-1 production) in
vessel walls; reduced lesion burden in distal vessels; and,
Figure 7. Collagen content in the different vasculature is not affected by DHA feeding. A, Collagen
content in the aortic root of studied groups. Representative images of aortic roots of apoE/
(apolipoprotein E–null) mice fed with an HFD alone or an HFD and DHA for 12 weeks, stained for martius
scarlet blue. Collagen stains bright blue. Scale bars=100 lm. B, Quantification of the collagen content
within the aortic roots of the 2 studied groups, measured as a percentage of the total lesion area. C,
Collagen content in BCAs. Representative images of BCA of apoE/ mice fed with an HFD alone or an HFD
and DHA for 12 weeks, stained for martius scarlet blue. Collagen stains bright blue. Scale bars=100 lm. D,
Quantification of the collagen content within the BCAs of the 2 studied groups measured as a percentage of
the total lesion area. Data are shown as meanSEM, n=7 per group, analyzed by unpaired Student t test,
P=ns. BCA indicates brachiocephalic artery; DHA, docosahexaenoic acid (22:6n-3); HFD, high-fat diet.
Figure 8. Schematic showing the potential mechanism whereby DHA selectively leads to alterations in oscillatory shear in distal vessels,
reduced inflammation, and lower blood pressure. DHA indicates docosahexaenoic acid (22:6n-3); IL, interleukin; OSI, oscillatory shear index.
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consequently, lowered blood pressure. Further studies tar-
geting IL-1 for lowering hypertension directly in mice or
humans are warranted.
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Supplemental Methods 
 
Animals and Diets 
Male ApoE-/- mice were bred in-house at the University of Sheffield. Food and water 
were given ad libitum under a controlled environment (Temp. 22-25°C, humidity 55±5 
and 12h light cycle). Mice were housed individually from 8 weeks of age and 
randomly separated into one of two groups (n=12/group). The control group was fed 
a high fat, Western-type diet (HFD) containing 21% (w/w) fat, 0.15% (w/w) 
cholesterol and 0.296% (w/w) sodium (Special Diet Services, Witham, UK) whereas 
the DHA treated group received HFD and DHA (99% purified, Sigma-Aldrich, UK). To 
ensure that the mice received the same concentration of DHA on each individual day, 
the free fatty acid was mixed with jelly at equal and final concentrations of 
300mg/kg/day, and the mice were monitored daily for their fatty acid (jelly) intake. 
The method of using jelly to deliver drugs to mice was published recently by (30) and 
has shown to be an efficient way to deliver drugs to mice at the required 
concentrations. The mice were trained for at least one week with the jelly alone, and 
then the jelly containing DHA was given to the mice along with the HFD. 
All animal care and procedures were closely conducted under ASPA 1986.  
 
Blood pressure analysis 
Systolic and diastolic blood pressure was measured in the mice using a Visitech tail-
cuff system (Visitech Systems, NJ, USA) as described previously (32). Briefly, the 
mice were subjected to one week of training before starting the actual measurements 
in order to minimize stress levels. Blood pressure was measured in 4 mice per group, 
and 10 measurements per mouse per day were recorded for four different days per 
week for 12 weeks. The data were rejected if the systolic blood pressure was more 
than 200mmHg or less than 40mmHg, outside the 2SD of the mean or had fewer 
than 4 valid readings. Per week measurements were also rejected if they had fewer 
than 3 valid readings.  
 
Echocardiography 
To assess the effect of DHA feeding on cardiac function during the duration of the 
study, transthoracic echocardiogram (TE) was performed as previously described 
(33). Briefly, the mice (n=4/group) were anesthetised using isoflurane delivered in 
oxygen in an isolator before placing the mice in a supine position. To minimise 
excessive heat loss, which may affect the measurements, the mice were placed on a 
heated platform and continuous rectal temperature was monitored.  
During recording, the mice were maintained on approximately 0.5-1.5% (v/v) 
isoflurane in oxygen, delivered via a nose cone. The level of anesthesia was adjusted 
to achieve a heart rate close to 500 ± 125bpm. To allow smooth image acquisition, 
the mouse chest wall was depilated and ultrasound gel was applied (Aquasonics 100 
Gel, Parker Labs Inc. New Jersey, U.S).  
Left ventricular (LV) function was recorded in the short axis view at the level of the 
mid-papillary muscles, whereas M-mode measurements were made for LV wall and 
cavity dimension (LVIDd). Ejection fraction (%EF), fractional shortening (%FS) and 
corrected LV mass (LVM) were assessed using automated analysis.  
 
Plasma profiles 
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 The blood was collected using cardiac puncture and plasma separated by 
centrifugation at 3000g over 5 minutes, collected and stored at -80oC prior to 
analysis. The inflammatory markers (IL-6, IL-8, RANTES, and MCP) were measured 
in the plasma using a cytometric bead array (CBA; BD Bioscience) according to 
manufacturer’s recommendations. Lipid profiles (total cholesterol, LDL and 
HDL/cholesterol ratio) were measured in the Clinical Biochemistry Laboratory at the 
Royal Hallamshire Hospital, Sheffield, UK. 
 
Preparation of samples for erythrocyte fatty acid analysis 
Freshly collected blood (by cardiac puncture) was collected into 4ml EDTA tubes (4 
pooled samples of RBCs from 4 different mice per group with a minimum volume of 
1mL). The blood samples were centrifuged for 5 minutes at 3000g and the plasma 
and buffy coat were aspirated and discarded. The tubes containing red cell fractions 
were then labelled and stored at -800C until sent to BioLab, London, UK to conduct 
the analysis.  
 
Atherosclerosis analysis 
The extent of atherosclerosis was assessed in whole aortae by an en face method 
(35). In brief, the aortae were perfused firstly by PBS and then by 10% (v/v) formalin. 
After the exposure of the whole aortae and removal of the adherent fats and vessels, 
aortae were dissected from the levels of aortic valves to the aortic orifice of the 
diaphragm under a dissecting microscope. Aortae were then fixed in 10% (v/v) 
formalin overnight at 4oC and stored in PBS at 4oC until pinning was conducted.  
The aortae were opened longitudinally and stained with oil red O stain (ORS). For 
this, the aortae were rinsed in 60% (v/v) isopropanol and stained with 0.3% (w/v) Oil 
Red O (Sudan IV; Sigma O0625) in PBS for 30min followed by destaining for 20min 
in 60% (v/v) isopropanol and further washing in distilled water. The stained aortae 
were pinned on a wax filled petri dish (15cm) using micro-needles (Fine Science 
Tools, Heidelberg, Germany). Images were recorded using a digital camera 
connected to light microscope at 15x magnification. Lesion areas were analysed 
using a NIS-elements analysis software system (Nikon, UK). Atherosclerotic lesion in 
the whole aortae, arch and descending parts were quantified as % of the total 
surface area. 
A second assessment of atherosclerosis was conducted in cross-sectional aortic root 
and brachiocephalic sections as described (34). Briefly, the hearts and 
brachiocephalic arteries (first branch of the aortic arch) were collected and stored in 
10% (v/v) formalin overnight at 4oC and then in PBS until they were embedded in 
paraffin wax. The paraffin-embedded hearts (at the level of aortic valves) and 
brachiocephalic arteries were serially sectioned using a Leica RM2135 microtome 
(Leica Microsystems, Wetzlar, Germany). Sections (5μm thickness) were collected 
and stained with Alcian Blue & Elastic Van Gieson (AB/EVG) as described (30).  
 
Analysis of Collagen content 
Collagen content in aortic and brachiocephalic sections were measured in martius 
scarlet blue (MSB) positive stained areas as described (30) and expressed as a 
percentage of the total surface area. In brief, the tissues were dewaxed and 
rehydrated in xylene and graded alcohols. The tissues were then stained with 1% 
(w/v) Celestine blue for 5 minutes, drained, and stained with Harris’ haematoxylin for 
5 minutes.  
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 After rinsing in water and differentiating in acid alcohol for few seconds, the tissues 
were exposed to hot running water for 5 minutes and rinsed in 95% (v/v) ethanol and 
then stained with martius yellow (0.5% (w/v) martius yellow, 2% (w/v) 
phosphotungstic acid in 95% (v/v) ethanol) for 2 minutes.  
 
The sections were then stained with Ponceau de xylene (1% (w/v) ponceau de 
xylene in 2% (v/v) glacial acetic acid) for 10 minutes and differentiated in 1% (w/v) 
phosphotungstic acid for 5 minutes. After draining of the stained sections, the tissues 
were stained with methyl blue (5% (w/v) methyl blue in 10% (v/v) glacial acetic acid) 
for 10 minutes and rinsed in 1% (v/v) acetic acid for 10 minutes. The sections were 
then dehydrated through graded alcohols and xylene and mounted using DPX 
mounting media. Analysis was performed using NIS-Element software. 
Alcohols and xylene were purchased from Thermo Fisher Scientific whereas all 
stains and DPX resin were obtained from VWR International Ltd (Lutterworth, UK) 
unless otherwise stated. 
 
Statistical analysis 
Data are expressed as mean ± SEM and analysed using prism software (Version 6, 
GraphPad, San Diego, CA). Blood pressure data were analysed by 2-way ANOVA 
followed by Tukey’s post-test. For the two-group comparison, data were analysed by 
unpaired Student t test for normally distributed data. Statistical significance was 
achieved when p<0.05.  
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